Furthermore, literature showed that GLP-1 had been approved by FDA to treat obesity, served as an anti-obesity agent mainly through reducing appetite or enhancing satiety in central nervous system (Srivastava and Apovian, 2018). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.